Today the Therapeutic Goods Administration (TGA) announced a Final Decision to down-schedule certain low-dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine). The decision allows for products approved by the TGA containing low-dose CBD: […]